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Background: Psoriatic arthritis (PsA) has been shown to be equivalent
to rheumatoid arthritis in its effect on patients’ functional disability.
There may be problems specific to PsA, related to skin disease
and impact on psychosocial functioning. PsA patients who fail conven-
tional DMARDs have demonstrated short-term improvement in
physical functioning measured by the health assessment questionnaire
(HAQ) on anti-TNF therapy but more long-term data is needed. We aim
to estimate HAQ progression for patients with PsA while on established
conventional or anti-TNF treatment for at least one year.
Methods: Patients who entered into the PsA database at the RNHRD,
Bath between 1985–2009 were included. Patients are asked to
complete a HAQ at their regular consultation. Annual HAQ progression
was estimated in patients on established treatment based on the
following model. An initial period of HAQ improvement was excluded
from the analysis; this was assumed to be >3 months from treatment
commencement for patients on anti-TNF and >6 months for
conventional DMARD. A treatment course was included if at least 2
HAQ measurements were available more than 1 year apart. Thus,
changes in HAQ were calculated once patients were established on
treatment. The longest period within each treatment course without
drug change was selected. Patients were classified according to
combined DMARD and anti-TNF therapy, anti-TNF alone and DMARD
alone. Other covariates included number of previous DMARD and anti-
TNF treatments, disease duration, age and gender. Linear regression
models were fitted and separate estimates of HAQ progression were
made for each type of treatment.
Results: A total of 151 patients were included in the analysis,
comprising a total of 162 treatment courses (132 DMARD, 30 anti-
TNF). 52.3% of patients were female and average age at disease onset
was 37 years (IQR: 27–50). Median disease duration was 11 years
(IQR: 17–24). 51.4% of patients had large joint pattern of involvement
at disease onset, 29.1% had small joint disease and 10.8% had both.
The remainder had other patterns of joint involvement. The average
duration of follow up was similar between the anti-TNF and combined
therapy groups but shorter than the period of follow-up in the DMARD
group. The mean number of HAQ observations was similar across all
groups. Regression results found a significant progression in HAQ
score of 0.024 (95% CI 0.003, 0.0449) points per annum in patients on
conventional DMARDs alone while patients on anti-TNF had no
significant progression (0.0003, P¼0.99).
Conclusions: This study demonstrates that the initial HAQ improve-
ment on anti-TNF therapy is sustained once patients are established
on treatment and that further decline occurred in patients on
established conventional DMARD therapy.
Disclosure statement: E.K., Abbott - Unrestricted research grant.
N.M., Abbott - Unrestricted research grant. All other authors have
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Background: Golimumab (GLM), a new human anti-tumor necrosis
factor (TNF) monoclonal antibody, has shown efficacy in ankylosing
spondylitis (AS).
Methods: To assess GLM efficacy/safety in pts with active AS, 356 pts
were randomized (1.8:1.8:1 ratio) to SC GLM 50 or 100 mg or PBO q 4
weeks. Eligible pts had definite AS (modified NY criteria), BASDAI  4
and a back pain score of  4. At week 16, PBO or GLM 50 mg pts with
<20% improvement in total back pain and morning stiffness entered
early escape (EE) to GLM 50 and 100 mg q 4 weeks, respectively
(double-blind). At week 24, pts still receiving PBO crossed over to
blinded GLM 50 mg SC injections q 4 weeks; others continued regimen
through week 100, with evaluation 4 weeks later. Key data summaries
are based on randomized treatment groups with no statistical
comparisons; other summaries show observed data only by regimen
followed.
Results: As reported previously, the primary endpoint (proportion of
pts with ASAS20 at week 14) was achieved. Benefit seen at weeks 14
and 24 was maintained through week 104 (Table). BASMI linear scores
improved from baseline to week 52; improvements were also
maintained through week 104, as were improvements in SF-36 MCS
and PCS scores. Pts not responsive to GLM 50mg who increased to
100 mg had lower rates of ASAS response and less improvement in
other parameters vs other GLM-treated pts (Table). Adverse events
(AEs) through week 104 were reported for 94% of GLM pts (little
variation across GLM doses). Through week 104, 11% of GLM pts
had a serious AE; the rate of GLM injection-site reactions was 1.4%
(106/7705 inj) through week 104. There were no deaths.
Conclusions: Clinical improvements in AS pts previously seen at
week 24 were maintained through week 104, with no major differences
in efficacy/safety between GLM doses. GLM was generally well
tolerated through 2 yrs of this 5 yr study.
Placebo GLM 50 mg GLM 100 mg
Pts randomized 78a 138 140
ASAS 20b 30 (38.5%) 83 (60.1%) 100 (75.6%)
ASAS 40b 30 (38.5%) 77 (55.8%) 76 (54.3%)
ASAS partial 17 (21.8%) 44 (31.9%) 43 (30.7%)
BASDAIc 6.02 (1.36, 7.79) 2.65 (0.84, 6.08) 2.73 (1.08, 5.34)
BASFIc 4.93 (0.98, 7.07) 2.22 (0.52, 5.80) 1.77 (0.49, 4.79)
Note:  Intent-to-treat analysis aIncludes 35 pts who did not meet EE criteria at
week 16 and 41 pts who did. bn in response, (%). cmedian, (interquartile range).
**Includes 25 pts who entered EE from 50 to 100 mg.
Disclosure statement: A.B., J.B., A.D.v.d.H, L.D., Centocor Research
and Development, Inc. - Investigator for GO-RAISE, a clinical trial
sponsored by Centocor Research and Development, Inc. All other
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Background: Various modalities of treatment have been used and
recommended in the treatment of acute gout. These include drugs
such as colchicine, NSAIDs and oral prednisolone. Intramuscular
depot methylprednisolone (im MP) is currently used in the treatment of
rheumatoid arthritis as well as polymyalgia. However the response to
im MP in acute gouty arthritis in an inpatient setting (where there are
usually contraindications to NSAIDs) has not been previously
described in literature.
Methods: Eighteen case records of patients presenting with acute
gouty arthritis and referred to Rheumatology, between October 2008
and October 2009, were reviewed.
Results: Fourteen men and four women, with a mean age of 60 years
(range 55–88 years) were seen. Of the 18, 14 patients had a
previous history of chronic gout and 4 patients were newly diagnosed.
Sixteen patients had polyarticular gout (mainly bilateral wrists and
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knees) and the remaining 2 had monoarticular gout (1 knee, 1 wrist).
Seventeen patients had synovial fluid analysis, which revealed
negatively birefringent urate crystals, and 1 patient refused joint
aspiration. All patients had predisposing co-morbidities such as
diabetes (10), hypertension (15), CCF (5), chronic kidney disease (8)
and 2 patients had a history of chronic alcohol excess. Five patients
initially received NSAIDs and 3 had concomitant colchicine with all 5
showing a delayed response. All patients were given im MP 120 mg in
the gluteal region as a deep injection. All responded completely to im
yMP within 2 days with resolution of pain and swelling of inflamed
joints. All patients felt much improved and rated the treatment highly.
Conclusions: The latest BSR guidelines recommends the use of
steroids in the management of refractory cases of gout, i.e. patients
intolerant of or having contraindications to NSAIDS or colchicine. This
restricted indication is based mainly on the side effects to oral steroids
or lack of expertise with intra-articular injections.
We have shown that a single intramuscular methyl prednisolone
injection is highly effective, very convenient, patient acceptable and
safe treatment for gout particularly in elderly patients with multiple co-
morbidities.
As most cases of inpatient gout have comorbidities such as in our
series with contraindications to NSAIDs, we recommend the use of im
methyl prednisolone as the first-line treatment in such patients. It may
be a less painful alternative to intra-articular steroid injections and
safer than bigger doses of oral steroids (especially in diabetes).
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Acute gouty arthritis is uncommon in women (10–15%).
If it does occur, it occurs after the menopause. The percentage of
women who develop acute gout in the pre-menopausal state is
negligible and is usually associated with other co-morbidities such as
renal insufficiency or diuretic use. During pregnancy the serum uric
acid normally drops; therefore, it is unlikely for patients to develop
acute attacks. There have been some published cases of gout co-
existing with pregnancy but patients did not develop acute attacks
until delivery. Only 3 cases of acute gout in pregnancy have been
described in the literature.
Methods: We are presenting an unusual case of acute gouty arthritis in
a 31 year old lady who is 7 weeks pregnant.
Results: A 31-year-old obese pregnant woman presented with an
acute episode of right ankle pain. She was 7 weeks pregnant and has
been experiencing morning sickness since the start of pregnancy. She
had recurrent attacks of gout affecting her big toe over the preceding
8 months and was treated by her general practitioner with etoricoxib.
She had a past medical history of transient haematuria in 2007 with
normal ultrasound of the kidneys, IVU and cystoscopy. Other
co-morbidities included hypertension, hypothyroidism and type II
diabetes mellitus. She had a strong family history of gout, a brother
and a maternal uncle developing symptoms at 25 and 16 years,
respectively. On examination, she was obese (BMI of 48), BP of 160/
85. Urine dipstick showed 1þ protein. She could not weight bear with
evidence of right ankle joint synovitis. Aspiration of the ankle revealed
1.5 ml of turbid fluid, which tested positive for monosodium urate
crystals. She had a normal renal function and a high uric acid of
551mmol/l. Her urinary urate: creatinine ratio was 0.24 (0.25–0.35) with
a urate fractional execretion of 4% (7–18.6). Red cell hypoxanthine
guanine phosphoribosyl transferase and adenine phosphoribosyl
transferase enzyme activity were normal. She was treated with an
intra-articular and intramuscular injection of methyl prednisolone with
resolution of symptoms. She subsequently had further episodes that
were treated similarly during pregnancy.
Conclusions: Only 3 cases of acute gouty arthritis during pregnancy
were published. Kelsall et al. reported acute gouty attack affecting the
1st MTP in a 34-year-old female with renal impairment, low creatinine
clearance and a low fractional excretion of urate of 5.5% (8–10%).
Friedman et al. described a case of acute gout in a pregnant lady with
severe pre-eclampsia and Loeffler et al. described it with renal
impairment. This would be the fourth case described (Table).
Published cases of acute gout during pregnancy including our
present case and all patients’ characteristics
Disclosure statement: All authors have declared no conflicts of
interest.
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ACETONIDE FOR TREATMENT OF ACUTE FLARES AND
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Background: Current treatments for arthritis flares in gout (gouty
arthritis) are not effective in all patients and may be contraindicated in
many due to underlying comorbidities. Urate crystals activate the
NALP 3 inflammasome which stimulate production of IL-1b, driving
inflammatory processes. Targeted IL-1b blockade may be an alter-
native treatment for gouty arthritis. Canakinumab (ACZ885) is a fully
human monoclonal anti-IL-1b antibody with a long half-life (28 days).
Methods: This was an 8-weeks, dose-ranging, multicentre, blinded,
double-dummy, active-controlled trial of patients  18 to  80 years
with an acute gouty arthritis flare, refractory to or contraindicated to
NSAIDs and/or colchicine. Patients were randomized to 1 subcuta-
neous (sc) dose of canakinumab (10, 25, 50, 90, or 150 mg) or 1 intra
muscular (im) dose of triamcinolone acetonide (TA) [40 mg].
The primary variable was assessed 72 h post-dose, measured on a
0–100 mm VAS pain scale. Secondary variables included pain intensity
24 and 48 h post dose, time to 50% reduction in pain intensity and time
to recurrence of gout flares up to 8 weeks post dose.
Results: 200 patients were enrolled (canakinumab n¼143, TA n¼57)
and 191 completed the study. A statistically significant dose response
was observed at 72 h. The 150 mg dose reached superior pain relief
compared with TA starting from 24 h: estimated mean difference in
pain intensity on 0–100 mm VAS was -11.5 at 24 h, -18.2 at 48 h and
-19.2 at 72 h (all P<0.05). Canakinumab 150 mg provided a rapid
onset of pain relief: median time to 50% reduction in pain was reached
at 1 day with canakinumab 150 mg vs. 2 days for the TA group
(P¼0.0006). The probability of recurrent gout flares was 37% with
Canakinumab 150 mg vs. 45.4% with TA 8-weeks post treatment, a
relative risk reduction of 94% (P¼0.006). Serious adverse events (AEs)
occurred in 2 patients receiving canakinumab (appendicitis and carotid
artery stenosis) and 1 receiving TA (cerebrovascular disorder).
Investigator’s reported these events as not study drug related. There
were no discontinuations due to AEs.
Conclusions: Canakinumab 150 mg provided faster onset and super-
ior pain relief compared with TA for acute flares in gouty arthritis
patients refractory to or contraindicated to standard treatments.
Case Age Renal impairment Family history Tophi Renal stones Co-morbidities X-ray changes Pre-eclampsia
Friedman et al. (1958) 33 Yes Yes No No No Yes Yes
Loeffler et al. (1960) 27 Yes No No No No No No
Kelsall et al. (1994) 34 Yes No No No No No No
Present case 31 No Yes No Questionable Hypertension
Hypothyroidism
Obesity Diabetes
No No
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The 150 mg dose of canakinumab prevented recurrence of gout flares
with a relative risk reduction compared with TA of 94% at 8-weeks
post-dose and was well tolerated.
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Emma Mannan, Venkat Reddy, Christopher Pearce, James Peters,
Ian Giles and Mike Shipley
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Background: Patients with acute, hot, swollen joints commonly
present to general practitioners, emergency departments and/or
acute admitting teams rather than directly to rheumatology. It is
imperative to consider septic arthritis in the differential diagnosis of
these patients. The British Society of Rheumatology (BSR) has
produced guidelines for the management of this condition, which
include recommendations for early specialist referral and joint
aspiration of all patients with suspected septic arthritis. We examined
whether the initial management of patients with acute hot swollen
joint(s) at University College London Hospital (UCLH) follows BSR
guidelines.
Methods: For the period Feb to Nov 2009, appropriate patients were
identified by searching the UCLH database using the diagnostic terms,
‘‘pyogenic arthritis’’, ‘‘septic arthritis’’ and ‘‘gout’’; and from all joint
aspirate requests sent to microbiology. Medical notes were obtained
and any patients who had elective arthroscopies or chronic
(>6 weeks) symptoms were excluded. Data were collected on the
time taken from the onset of symptoms to specialist (orthopaedic/
rheumatology) referral and joint aspiration, collection of blood cultures
and antibiotic treatment with or without microbiology advice.
Results: Twenty patients were identified with hot swollen (18
monoarticular, 3 prosthetic) joint(s) of <2 weeks duration. Of whom,
3/20 (15%) were admitted directly to rheumatology, 7/20 (35%) to the
acute admissions unit, 3/20 (15%) to orthopaedic, 4/20 (20%) to a
medical team and 1/20 (5%) to general surgery. In 19 (95%) cases,
specialist (rheumatology/orthopaedic) advice was sought. Of 14 cases
not seen directly by specialists 9 (64%) were referred at 24–48 h and
5 (36%) at 48–192 h. All 20 patients had joint aspiration. In 9/20 (45%)
of cases, joint aspiration was performed in less than 6 h, 3/20 (15%)
cases at 6-24h and 6/20 (30%) cases at 24–192 h and was not
recorded in two patients. Of these, crystals were identified in two and
one was culture positive. Blood cultures were received for only 6/20
(30%) of cases and only clearly documented to have been taken prior
to antibiotic therapy and none were positive. Of 14/20 (70%) started on
antibiotic treatment empirically, only 6 (42%) were preceded by joint
aspiration. In the 6 patients not treated with antibiotics due to low
index of suspicion of septic arthritis, synovial fluid and blood cultures
were negative. Microbiology advice was sought in 10/20 (50%) of
cases by the admitting teams but the timing of this advice is unclear.
Conclusions: Despite the provision of 24 h rheumatology and
orthopaedic cover at UCLH, we found a significant delay in acute
medical firms seeking specialist advice on the management of patients
with acute, hot swollen joints with subsequent deviation from BSR
guidelines. Consequently, we plan to increase awareness of these
guidelines amongst medical firms at UCLH.
Disclosure statement: All authors have declared no conflicts of
interest.
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Anupam Paul and Shirley Rigby
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Background: Hot swollen joint is a common presentation and has a
wide differential diagnosis of which the most serious is septic arthritis
(SA), with a significant mortality and morbidity in case of inappropriate
management. Yet this treatable medical emergency is often treated
sub-optimally leading to adverse consequences. This audit has been
undertaken to assess our practice against the joint BSR and BHPR,
BOA, RCGP and BSAC guidelines published in 2006.
Methods: Data have been collected prospectively for all patients
either admitted with less than 2 weeks history of hot swollen joint or
developing this condition as an inpatient over 1-year period. Audit
standards suggested in the guideline has been the prime focus of this
audit.
Results: A total of 32 patients presenting with hot swollen joints have
been audited. Out of these, 13 patients were diagnosed to have septic
arthritis (SA) whereas 19 patients had another diagnosis (5 had
pseudogout, 4 had gout, 4 had seronegative arthropathy, 3 had soft
tissue infection, 1 had osteoarthritis, 1 had haemarthrosis and 1 had no
diagnosis). Out of 13 patients with septic arthritis, 8 were males and
5 were females. Out of 19 patients with another diagnosis, 8 were
males and 11 were females. The mean age of patients with septic
arthritis was 71 (range 43–94 years). The mean age of non-septic
arthritis patients was 66 (range 24–100 years).
Out of 32 patients, 22 patients (8 SA and 14 non SA) had their joint
aspirated prior to antibiotics. 10 patients (5 SA and 5 non SA) failed to
have their joints aspirated prior to antibiotics due to various reasons
(1 needle-phobic, 1 had obvious discharging pus, 2 went straight to
theatre, 1 had cellulitis, 1 was suspected to have some injury and no
reason documented in 4 patients).
Out of the 13 patients with SA, 5 were managed by rheumatologists
and 8 by orthopaedic surgeons. 2 of these 13 patients had prosthetic
joint SA and therefore were managed appropriately by orthopaedic
surgeons. In the 13 patients with SA, appropriate cultures were sent in
all patients (either from the initial joint aspiration or from later surgical
drainage), CRP was measured at baseline in all patients, ESR was
measured at baseline in 3 patients and all patients had serial
measurements of CRP and white cell count but not ESR. The initial
antibiotic choice was in keeping with national or local guidelines in 10
out of 13 patients and there was a delay in management in 2 patients
with SA. 1 of these patients was initially thought to have osteoarthritis
and the other was thought to have a joint injury.
Conclusions: This audit has revealed that about a third of patients
presenting with hot swollen joint fail to have a joint aspiration prior to
starting antibiotics. There is still considerable scope for improvement
in our management of hot swollen joints. Doctors working in the
‘frontline’ should be made aware of these guidelines in order to
improve our practice.
Disclosure statement: All authors have declared no conflicts of
interest.
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HEPATITIS C VIRUS INFECTION
Reem H. Abdellatif mohammed1, Hesham I. Elmakhzangy2,
Gamal Esmat2, Amira Gamal3, Fatma Mekky3, Nabil M. Ibrahim4 and
Mohammed A. Elhamid5
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Background: Chronic HCV viraemia has been known to provoke a
variety of autoimmune-like diseases referred to as extrahepatic
manifestations of chronic HCV infection. Egypt has an exceptionally
high prevalence of HCV infection, estimated to be between 10 and
15% of its 70 million population. The study aimed at evaluation of the
prevalence of extrahepatic rheumatological manifestations of chronic
HCV infection in Egyptian patients and its different clinical presenta-
tions in a way to illustrate the spectrum of these presentation in the
study group.
Methods: All chronic HCV patients attending the outpatient clinic of
the National Hepatology and Tropical Medicine Research Institute
(NHTMRI) through a period of 1 year were interviewed and subjected
to a questionnaire to screen those having rheumatological complaints
then referred to the rheumatologist for evaluation. Laboratory
investigations included complete blood picture, serum transaminases,
serum bilirubin, total proteins, serum albumin, serum urea and
creatinine, complete urinalysis, oral glucose tolerance test.
Serological assay included cryoglobulin profile, rheumatoid factor,
Poster Viewing I Wednesday 21 April 2010, 12:30-14:00 i61
